Weekly content update

Welcome to one of our new initiatives for 2025 - a short weekly summary of updates to HemOnc.org content. Updates occur across the wiki on a fairly regular basis, but it can be difficult to appreciate what has been updated, and when. Note that this summary does not include minor changes such as verification of existing content, formatting changes, typographical corrections, and so forth. These summaries are intended to be succinct; please consult our glossary for any unfamiliar abbreviations.
You can also receive these updates by following our LinkedIn account and/or joining our Google Groups mailing list.
==HemOnc.org Weekly Content Update (February 3-9, 2025)==
Given everything else happening in the past week, updates are slimmer than usual. For those of you who might not be aware, substantial support for HemOnc.org and the HemOnc knowledgebase comes from NCI funding, so we expect to be significantly impacted by the reduction in IDC rates. In addition to grant leadership in Rhode Island, funds go to Alabama, Arizona, Georgia, Massachusetts, North Carolina, Tennessee, and Washington state. Without exception, all sites involved had IDC rates well above 15%. Consider this as one example of many on the impact of the sudden and drastic cuts in the NIH indirect rate announced on Friday. Your local congressperson might be interested in hearing about this.
One trials-in-context comment for you this week, from Dr. Alaina J. Brown, MD, MPH (section editor of gynecological malignancy): “The final survival analysis update to the EMPOWER-Cervical1 trial further supports the consideration of cemiplimab as an agent that may be used in recurrent cervical cancer after failure of initial platinum-based therapy. A significant improvement in OS was noted in the cemiplimab group as compared to chemotherapy (11.7 mo vs 8.5 mo). Cemiplimab has activity regardless of PD-L1 status and provides an additional option for consideration in the management of this population, which currently has limited effective therapies in the metastatic recurrent setting.”
Note: in addition to trying to keep pace with the newly published literature, we find older content that meets HemOnc.org eligibility requirements from time-to-time. Unless otherwise noted, content additions listed here are from literature published within the last 12 months.
New Regimens
* Nivolumab monotherapy (MSI-H CRC)
* SOXRC (perioperative gastric cancer)
New Studies
* DRAGON IV/CAP 05 (positive ph3 of perioperative SOXRC in gastric cancer)
* INTEGRATE IIa (positive ph3 of regorafenib in refractory gastric cancer)
New Study Updates (includes efficacy, HRQoL, and PRO updates)
* CheckMate 8HW (MSI-H CRC)
* CLL12 (untreated CLL)
* EMPOWER-Cervical 1 (cervical cancer)
HRQoL analysis additions:
* AVAPERL (nsqNSCLC, 2013)
* BCIRG 2006 (HER2+ breast cancer, 2013)
* BEACON (breast cancer, 2017)
* ECOG E2100 (breast cancer, 2011)
* EF-14 (GBM, 2017)
* ELOQUENT-2 (RRMM, 2018)
* EORTC 18991 (melanoma, 2009)
* FALCON (HR+ breast cancer, 2018)
* GADOLIN (iNHL, 2016)
* GALLIUM (FL, 2020)
* GEST (pancreatic cancer, 2017)
* GOG 172 (ovarian cancer, 2007)
* IPASS (nsqNSCLC, 2011)
* JASPAC 01 (pancreatic cancer, 2021)
* KEYNOTE-062 (gastric/GEJ, 2021)
* KEYNOTE-181 (esophageal cancer, 2021)
* LARCS (rectal cancer, 2011)
* Lung-MAP (sqNSCLC, 2023)
* MIROX (CRC, 2016)
* RTOG 0825 (GBM, 2021)
* TOURMALINE-MM1 (RRMM, 2018)
Other
* How I treat blastic plasmacytoid dendritic cell neoplasm
Selected links
# https://hemonc.org/wiki/Cervical_cancer#Cemiplimab_monotherapy
# https://hemonc.org/wiki/Gastric_cancer#SOXRC 
==HemOnc.org Weekly Content Update (January 27- February 2, 2025)==
Due to a great deal of uncertainty about the reliability of websites maintained by the US government, we undertook a conversion away from links to the .gov domain, when feasible. We have migrated all PMID and PMCID links from MEDLINE to Europe PMC (hereafter, “EuroPMC”), across 542 pages. What this means for you as a user is that instead of the “PubMed” link with each reference on HemOnc.org, there is now a “EuroPMC” link instead. One added benefit of the EuroPMC format is that full free text, if available, is present on the linked page; conversely, PubMed Central required an additional link to get to the full free text. As with any change of this magnitude, some errors may have crept in - please notify us at contact@hemonc.org if you come across anything that is not working as expected!
In addition to this change, we added a number of “How I Treat” articles from the past several months, more HRQoL analysis updates, and have some thoughts about DESTINY-Breast06 in light of the recent expanded approval for T-DXd:
From Dr. Gayathri Nagaraj, MD (section editor of breast cancer): “The DESTINY-Breast06 phase 3 trial evaluated fam-trastuzumab deruxtecan-nxki (T-DXd; Enhertu) against physician’s choice of chemotherapy in patients with hormone receptor–positive (HR+), HER2-low or HER2-ultralow metastatic breast cancer who had undergone at least one or more lines of endocrine therapy without prior chemotherapy for metastatic disease. The results demonstrated significantly improved progression-free survival (PFS) in both HER2-low and HER2-ultralow patients with T-DXd, offering a more effective option than chemotherapy.
These results challenge the traditional categorization of breast cancers by HER2 expression and highlight the need for precise HER2 testing, as current methods may not reliably distinguish HER2-low from HER2-ultralow. Standardizing testing protocols is essential to identify patients most likely to benefit from T-DXd.  While the drug has a favorable safety profile, monitoring for adverse effects like interstitial lung disease remains critical. Ongoing research and real-world data will be key to understanding its long-term safety and efficacy in diverse patient populations.”
Note: in addition to trying to keep pace with the newly published literature, we find older content that meets HemOnc.org eligibility requirements from time-to-time. Unless otherwise noted, content additions listed here are from literature published within the last 12 months.
New Regimens
* Fludarabine & Treosulfan for allogeneic HCST
New Studies
* ALEXANDRA (negative RCT of adding atezolizumab to standard adjuvant chemotherapy in TNBC)
* ESOPEC (positive RCT of perioperative FLOT for esophageal adenocarcinoma)
New Study Updates (includes efficacy, HRQoL, and PRO updates)
* HOBOE (HR+ breast cancer)
* KEYNOTE-564 (RCC)
* NATALEE (HR+ breast cancer)
HRQoL analysis additions:
* ADAURA (EGFRm NSCLC, 2022)
* ALCYONE (NDMM, 2021)
* ARAMIA (prostate cancer, 2021)
* ASCENT (TNBC, 2022)
* CASTOR (RRMM, 2021)
* EMPOWER-Cervical 1 (cervical cancer, 2022)
* EMPOWER-Lung 1 (NSCLC, 2022)
* ENDEAVOR (RRMM, 2019)
* ENTER (NSCLC brain metastases)
* ENZAMET (prostate cancer, 2021)
* LUME-Colon 1 (CRC, 2019)
* MAPS (MPM, 2019)
* NETTER-1 (midgut NET, 2018)
* ORIENT-11 (nsqNSCLC)
* SPCG-13 (prostate cancer, 2022)
* SUNLIGHT (CRC)
New Approvals
* Initial FDA approval of treosulfan for allogeneic HSCT (as Grafapex), based on MC-FludT.14/L
* Expanded FDA label for trastuzumab-deruxtecan for HER2-low breast cancer, based on DESTINY-Breast06
Other
How I Treat additions:
* How I approach intersectionality in hematopoietic stem cell transplantation
* How I manage iron overload in the hematopoietic cell transplantation setting
* How I treat adult Ph+ ALL
* How I treat ETP-ALL in children
* How I treat infant acute lymphoblastic leukemia
* How I treat iron overload in adult MDS
* How I treat older patients with Ph/BCR-ABL-negative acute lymphoblastic leukemia
* How I treat older patients with relapsed/refractory diffuse large B-cell lymphoma
* How I treat Philadelphia chromosome-like acute lymphoblastic leukemia in children, adolescents, and young adults
* How I treat postimmunotherapy relapsed B-ALL
* How I treat sickle cell disease with gene therapy
Selected links
# T-DxD page
# How I Treat page
==HemOnc.org Weekly Content Update (January 20-26, 2025)==
Note: in addition to trying to keep pace with the newly published literature, we find older content that meets HemOnc.org eligibility requirements from time-to-time. Unless otherwise noted, content additions listed here are from literature published within the last 12 months.
Fewer updates this week, after last week’s marathon of new additions! This week, we’re rolling out a new trials-in-context feature, where our editors provide their viewpoint on one or two of the most notable new additions over the past week. To start us off, we’ve got Dr. Rubinstein discussing AURIGA, and Dr. Nagaraj discussing TROPION-Breast01:
From Dr. Samuel Rubinstein, MD, MSCI (section editor of plasma cell neoplasms): “The AURIGA study randomized patients with newly diagnosed multiple myeloma naive to daratumumab who had measurable minimal residual disease following autologous stem cell transplantation to receive daratumumab and lenalidomide (DR) or lenalidomide (R) maintenance, with a primary endpoint of MRD-negativity by next generation sequencing at a sensitivity level of 10-5. Patients randomized to receive DR maintenance were meaningfully likelier to achieve MRD negativity and experienced longer progression free survival than those receiving R maintenance. The role of daratumumab in the maintenance setting for patients who receive daratumumab-based inductions is not examined by this trial. As such, this trial may not inform practice in settings where pretransplant inductions include daratumumab.”
From Dr. Gayathri Nagaraj, MD (section editor of breast cancer): “The TROPION-Breast01 trial assessed datopotamab deruxtecan (Dato-DXd), a TROP2-directed antibody-drug conjugate, against investigator’s choice of chemotherapy in patients with inoperable or metastatic HR-positive, HER2-low/negative breast cancer after endocrine therapy and at least one chemotherapy. The trial showed significant PFS improvement with manageable safety, though OS data was not statistically significant. As the third approved antibody-drug conjugate in this setting, optimal sequencing remains uncertain.”
New Regimens
* Bevacizumab, Durvalumab, TACE in nonmetastatic HCC
* Carboplatin & Fluorouracil in neoadjuvant ESCC
* Carboplatin & Paclitaxel (CP) in neoadjuvant ESCC
* Datopotamab deruxtecan in HR+ BC
* Datopotamab deruxtecan in NSCLC
* Lenalidomide & SC Daratumumab in MM maintenance
* Lenvatinib, Pembrolizumab, TACE in nonmetastatic HCC
New Studies
* AURIGA (positive RCT of Dara-Len maintenance in CD38-naive NDMM after auto HSCT)
* CheckMate 914 part B (negative RCT of adjuvant nivolumab in RCC)
* EMERALD-1 (positive RCT of bevacizumab, durvalumab, TACE in nonmetastatic HCC)
* LEAP-012 (partially positive RCT of lenvatinib, pembrolizumab, TACE in nonmetastatic HCC)
* LEONARDA-1 (positive RCT of fulvestrant + lerociclib in 2L+ HR+ BC)
* Noronha et al. 2024b (noninferiority RCT of neoadjuvant platinum + paclitaxel in ESCC)
* SIERRA (positive RCT of iodine I 131 apamistamab in r/r AML)
* TROPION-Breast01 (positive RCT of Dato-DXd in HR+ BC; basis of FDA approval)
* TROPION-Lung01 (partially positive RCT of Dato-DXd in NSCLC)
* ZKAB001-LEES-2020-07 (positive RCT of 1L CE + socazolimab in ES-SCLC)
New Study Updates (includes efficacy, HRQoL, and PRO updates)
* KATHERINE (adjuvant T-DM1 in HER2+ BC with residual invasive disease)
New Guidelines
* ASCO neoadjuvant ovarian cancer (2025)
New approvals
* Initial FDA approval for datopotamab deruxtecan (Datroway) in HR+ BC
Other
* Created datopotamab deruxtecan page
* Created iodine I 131 apamistamab page
* Created lerociclib page
* Created socazolimab page
* Completed the migration of generic superior/inferior results language to language that confers a sense of magnitude: 1) longer/shorter survival; 2) higher/lower rates; 3) better/worse scores; 4) more/less toxicity.
Selected links
# AURIGA: https://hemonc.org/wiki/Multiple_myeloma,_consolidation_and_maintenance#Lenalidomide_&_SC_Daratumumab
# TROPION-Breast01: https://hemonc.org/wiki/Breast_cancer,_ER-positive#Datopotamab_deruxtecan_monotherapy
==HemOnc.org Weekly Content Update (January 13-19, 2025)==
Note: in addition to trying to keep pace with the newly published literature, we find older content that meets HemOnc.org eligibility requirements from time-to-time. Unless otherwise noted, content additions listed here are from literature published within the last 12 months.
You will notice a much larger than normal number of updates in this week’s content update. Most of these are health-related quality of life (HRQoL) or patient-reported outcomes (PRO) analyses. These article types were not a historical focus for HemOnc.org, with our first years focused on building out the primary analysis literature. In recent years we have begun to routinely include HRQoL/PRO updates as they are identified, but older ones were not systematically collected until now. This process will continue for a few more weeks at least, so you might expect to see even more additions! Once we feel that we have added the readily identifiable literature, we will begin to surface some of the summary findings in the tables found above each regimen. This will help us meet one of our goals that is supported by our National Cancer Institute U24 funding (to conduct a systematic literature search for clinical trial reports that focus on HRQoL and toxicity analyses).
Question of the week: What key elements of HRQoL should we include in the tables? For example, many trials use standard instruments such as QLQ-C30; should we report these results?
New Regimens
* BR & Acalabrutinib (1L MCL)
* CapeOx & Sintilimab (1L gastric cancer)
* Carboplatin & Pemetrexed (1L nsqNSCLC, elderly patients)
* CF & Serplulimab (1L ESCC, basis of NMPA approval)
* Docetaxel monotherapy (1L nsqNSCLC, elderly patients)
* EP & Toripalimab (ES-SCLC)
* Enzalutamide & Talazoparib (1L HRD+ mCRPC)
* Palbociclib & Tamoxifen (1L HR+ breast cancer)
* TH-ECH (neoadjuvant HER2+ breast cancer)
New Studies
* ASTRUM-007 (positive RCT of CF & Serplulimab in ESCC, published in 2023)
* B-FAST cohort C (negative RCT of atezolizumab in TMB-selected NSCLC, published in 2022)
* CAIRO5 (partially positive RCT of FOLFOXIRI+Bev in initially unresectable CRC, published in 2023)
* EOC103A3101 (positive RCT of entinostat + exemestane in 2L HR+ breast cancer, published in 2023)
* EXTENTORCH (positive RCT of EP + toripalimab in ES-SCLC)
* JAVELIN Lung 100 (negative RCT of avelumab in 1L NSCLC, published in 2023)
* JCOG1210/WJOG7813L (non-inferior RCT of carbo-pem vs docetaxel in 1L nsqNSCLC, elderly patients, published in 2020)
* JCOG2007 (negative RCT of chemo + ipi/nivo in 1L NSCLC)
* LY-TM-LPS-2016-01 (negative RCT of cisplatin + paclitaxel liposomal in 1L sqNSCLC, published in 2021)
* MAGRIT (negative RCT of MAGE-A3 immunotherapeutic in MAGE-A3+ NSCLC, published in 2016)
* MIRROS (negative RCT of idasanutlin + IDAC in r/r AML, published in 2022)
* NNBC 3-Europe (negative RCT of FEC-D in NNBC, published in 2023)
* Noguchi et al. 2015 (non-inferior RCT of q3mo goserelin in 1L HR+ premenopausal breast cancer, published in 2015)
* ORIENT-16 (positive RCT of CapeOx & Sintilimab in 1L gastric cancer, published in 2023)
* PATHWAY (positive RCT of Palbociclib + Tamoxifen in 1L HR+ breast cancer)
* PRIMULA (negative RCT of aza+pracinostat in AML)
* TALAPRO-2 (positive RCT of enza + talazoparib in 1L HRD+ mCRPC, published in 2023)
* TE-3 (negative RCT of infusional BEP in good-prognosis germ cell tumor, published in 2017)
* TRIBE2 (positive RCT of FOLFOXIRI+Bev in 1L CRC, published in 2020)
* TROIKA (equivalence RCT of trastuzumab biosimilar in HER2+ breast cancer, published in 2022)
New Study Updates (includes efficacy, HRQoL, and PRO updates)
2010
* 20020408 (CRC)
* EGF30001 (breast cancer)
2011
* Nordic IFN trial (melanoma)
2012
* CC-5013-MDS-004 (5q- MDS)
* RADAR (prostate cancer)
* VISTA (NDMM)
2013
* CA184-024 (melanoma)
* COMFORT-II (MF)
* COU-AA-302 (prostate cancer)
* NCIC-CTG/AGITG CO.20 (KRAS-wt CRC)
2014
* CA031 (NSCLC)
* PARAMOUNT (nsqNSCLC)
2015
* E7389-G000-301 (breast cancer)
* NIMBUS (RRMM)
* PALETTE (STS)
* SOFT (HR+ breast cancer)
* TEXT (HR+ breast cancer)
2016
* BRIGHT (iNHL/MCL)
* COMPARZ (RCC)
* COMPLEMENT 2 (CLL)
* Gronchi et al. 2012 (high-risk STS)
* QUIREDEX (SMM)
* REVEL (NSCLC)
* RTOG 0167 (NSCLC)
* SPCG-7 (prostate cancer)
2017
* GHSG HD15 (cHL)
* NAPOLI-1 (pancreatic cancer)
2018
* EF-14 (GBM)
* INO-VATE ALL (B-ALL)
* PANORAMA 1 (RRMM)
* RTOG 94-13 (prostate cancer)
2019
* ABCSG-18 (HR+ breast cancer)
* ATGFamilyStudy (aGVHD)
* BFORE (CML)
* CeTeG/NOA-09 (GBM)
* HOVON87/NMSG18 (NDMM)
* MILES-3 (NSCLC)
* MILES-4 (NSCLC)
* PROMID (NET)
* PROSPER (prostate cancer)
* TITAN (mHSPC)
* Tugela (CLL)
2020
* ASCEND (CLL)
* CADENZA (CAD)
* CASSIOPEIA part 1 (NDMM)
* GCLLSG CLL10 (CLL)
* ICON8 (ovarian cancer)
* KATHERINE (HER2+ breast cancer)
* OPTIMISMM (RRMM)
* PANTHER (breast cancer)
2021
* CheckMate 078 (2L+ NSCLC)
* GCLLSG CLL14 (CLL)
* GHSG HD14 (cHL)
* IMbrave150 (HCC)
* IMvigor211 (urothelial carcinoma)
* KEYNOTE-061 (gastric cancer)
* MEDALIST (MDS)
* MYSTIC (NSCLC)
* NALA (HER2+ breast cancer)
* OLYMPUS (UTUC)
* POLLUX (RRMM)
* RATIONALE 307 (sqNSCLC)
2022
* ANDROMEDA (AL amyloidosis)
* CADINAL (CAD)
* CANDOR (RRMM)
* CheckMate 9ER (RCC)
* CLEAR (RCC)
* CWS/RMS-96 (Ewing sarcoma)
* DART01/05 GICOR (prostate cancer)
* ECOG E5103 (breast cancer)
* FURLONG (EGFRm NSCLC)
* INVICTUS (GIST)
* KEYNOTE-048 (head & neck cancer)
* KEYNOTE-426 (RCC)
* LNH03-6B (DLBCL)
* ORIENT-11 (nsqNSCLC)
* PRIMA (ovarian cancer)
* QUIREDEX (SMM)
* RESONATE-2 (CLL)
2023
* ACE (HR+ breast cancer)
* ADMIRAL (FLT3+ AML)
* ALESIA (ALK+ NSCLC)
* ALTA-1L (ALK+ NSCLC)
* CANDOR (RRMM)
* CT-P6 3.2 (HER2+ breast cancer)
* DATA (HR+ breast cancer)
* GCLLSG CLL14 (CLL)
* INTRIGUE (GIST)
* JUPITER-02 (NPC)
* KEYNOTE-119 (TNBC)
* KEYNOTE-240 (HCC)
* KEYNOTE-604 (SCLC)
* MOMENTUM (MF)
* QUAZAR AML-001 (AML)
* RATIONALE-303 (NSCLC)
* TROIKA (HER2+ breast cancer)
* UNICANCER-PRODIGE 23 (rectal cancer)
* ZUMA-7 (DLBCL)
2024
* ADAURA (EGFRm NSCLC)
* ALESIA (ALK+ NSCLC)
* CRUK-2004-001621-16 (FL)
* FURLONG (EGFRm NSCLC)
* HOVON 105/ALLG NHL 24 (PCNSL)
* KEYNOTE-394 (HCC)
* MAGNITUDE (HRD+ prostate cancer)
* MAVORIC (CTCL)
* NORA (ovarian cancer)
* ORIENT-15 (ESCC)
* POSEIDON (1L NSCLC)
* RATIONALE-301 (HCC)
New approvals
* FDA label for sotorasib: “Approved with panitumumab for adult patients with KRAS G12C-mutated metastatic colorectal cancer (mCRC), as determined by an FDA-approved test, who have received prior fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy.” (based on CodeBreaK 300)
* FDA label for acalabrutinib: “Approved with bendamustine and rituximab for adults with previously untreated mantle cell lymphoma (MCL) who are ineligible for autologous hematopoietic stem cell transplantation (HSCT).” (based on ECHO)
* FDA label for acalabrutinib: “Granted traditional approval as a single agent for adults with previously treated MCL.”
Other
* Renamed BRCAm prostate cancer page to HRD-positive prostate cancer, to reflect a broader scope
* Created a new “backbone” page to maintain a list of commonly understood backbones - two or more drugs that form the foundation for subsequent additive studies.
==HemOnc.org Weekly Content Update (January 6-12, 2025)==
Note: in addition to trying to keep pace with the newly published literature, we find older content that meets HemOnc.org eligibility requirements from time-to-time. Unless otherwise noted, content additions listed here are from literature published within the last 12 months.
The main theme of this week is catching up with older trials and updates that had slipped through the cracks, including a new study type that we hadn’t focused on before: TWiST/Q-TWiST analyses. Notable newly added studies include AMBASSADOR and HELEN-006.
New Regimens
* ADT & Rezvilutamide for mHSPC
* Bicalutamide & Leuprolide for nmHSPC
* Carboplatin & Docetaxel as NACT for NSCLC
* Carboplatin, Pemetrexed, Ivonescimab for TKI-exposed EGFRm NSCLC
* Cisplatin & nab-Paclitaxel for 1L TNBC
* nab-Paclitaxel, Pertuzumab, Trastuzumab for neoadjuvant HER2+ breast cancer
* Pembrolizumab for adjuvant urothelial carcinoma
* Talquetamab & Teclistamab for RRMM
New Studies
* ALTA-3 (negative RCT of brigatinib [vs alectinib] after crizotinib for ALK+ NSCLC, published in 2023)
* AMBASSADOR (positive RCT of adjuvant pembrolizumab for urothelial cancer)
* COMET-2 (negative RCT of cabozantinib in mCRPC, published in 2018)
* DUBLIN-3 (positive RCT of docetaxel + plinabulin in 2L+ NSCLC)
* EE2012 (positive RCT of American vs European treatment approach for Ewing sarcoma, published in 2022)
* HELEN-006 (positive RCT of de-escalated neoadjuvant treatment for HER2+ breast cancer)
* IFCT-0702 (negative RCT of platinum + docetaxel in relapsed NSCLC, published in 2015)
* INTRAPID Lung 037 (negative RCT of bintrafusp alfa in 1L NSCLC, published in 2023)
* Kim et al. 2012 (negative RCT of CRT vs CT for adjuvant gastric cancer)
* LCSG 853 (negative RCT of adjuvant CAP in NSCLC, published in 1994)
* LEAP-011 (negative RCT of lenvatinib & pembrolizumab for urothelial carcinoma, published in 2023)
* MARS 2 (negative RCT of extended pleurectomy decortication in pleural mesothelioma)
* Noronha et al. 2024 (negative RCT of TP vs TPF as NACT for oral cancer)
* ORIENT-31 (positive RCT of sintilimab + IBI-305 in EGFRm NSCLC, published in 2022)
* RedirecTT-1 (phase 1b/2 of talquetamab & teclistamab in RRMM)
* TAX3503 (negative RCT of ADT & Docetaxel for biochemically recurrent prostate cancer)
* TREATT (negative RCT of tranexamic acid to prevent bleeding in severe thrombocytopenia)
* Wang et al. 2022 (positive RCT of Cisplatin & nab-Paclitaxel in 1L TNBC)
* WJTOG9903 (negative RCT of neoadjuvant CRT in NSCLC, published in 2012)
New Study Updates (includes efficacy, HRQoL, and PRO updates)
* BRIM8 (BRAFm melanoma, published in 2019)
* CAO/ARO/AIO-04 (rectal cancer, published in 2020)
* CARTITUDE-4 (relapsed/refractory multiple myeloma)
* CheckMate 067 (melanoma)
* CheckMate 649 (gastric cancer, published in 2023)
* CLTR0310-301 (AML, published in 2021)
* COSMIC-311 (differentiated thyroid cancer, published in 2022)
* CROWN (ALK+ NSCLC, published in 2022)
* EMPOWER-Lung 3 part 2 (NSCLC, published in 2023)
* EORTC 22033-26033 (low-grade glioma, published in 2016)
* EORTC 24954 (head & neck cancer, published in 2013)
* FLAGS (gastric cancer, published in 2013 & 2015)
* GOG 240 (cervical cancer, published in 2015)
* ICON6 (ovarian cancer, published in 2017)
* JMEN (NSCLC, published in 2012)
* ORIENT-31 (EGFRm NSCLC, published in 2023)
* OTT-0101 (localized prostate cancer, published in 2021)
* Patil et al. 2019a (LAHNSCC, published in 2021)
* POLO (BRCAm pancreatic cancer, published in 2023)
* PROTECT (RCC, published in 2021)
* RANGE (urothelial carcinoma, published in 2020)
* REFLECT (HCC, published in 2021)
* SB3-G31-BC (HER2+ breast cancer, published in 2019)
* SOC-1 (platinum-sensitive, relapsed ovarian cancer)
* SQUIRE (sqNSCLC, published in 2016)
* TAGS (gastric cancer, published in 2020)
* TTCC 2503 (LAHNSCC, published in 2020)
Selected links
# Adjuvant pembrolizumab for urothelial cancer (AMBASSADOR)
# Neoadjuvant nab-Paclitaxel, Pertuzumab, Trastuzumab for HER2+ breast cancer (HELEN-006)
== HemOnc.org Weekly Content Update (December 30, 2024 - January 5, 2025) ==
Question for you: When a study meets one but not another co-primary endpoint, should we report this as a positive study, or a negative study? That is, should we color the efficacy box as red/blue (positive coloration) or pale yellow (negative coloration).
New Regimens
* SC nivolumab for 2L ccRCC
* Lumrotatug for relapsed ITP
* Danicopan & Eculizumab/Ravulizumab for PNH
New Studies
* Bramhall et al. 2001 (negative RCT of marimastat in 1L pancreatic cancer)
* Bramhall et al. 2002 (negative RCT of gemcitabine & marimastat in 1L pancreatic cancer)
* CanStem111P (negative RCT of napabucasin in 1L pancreatic cancer, from 2023)
* Destiny-Breast06 (positive RCT of trastuzumab deruxtecan in HER2-low MBC without prior chemotherapy exposure)
* CheckMate 67T (positive RCT of SC nivolumab in ccRCC; basis of FDA approval)
New Study Updates
* CHOICE-01 (RCT of toripalimab plus chemotherapy for 1L NSCLC)
* ESTIMABL2 (RCT of radioiodine-free approach after thyroidectomy for DTC)
* ALPINE (RCT of zanubrutinib for r/r CLL/SLL)
New Guidelines
* ESMO melanoma (2024)
* ESMO Pan-Asian adapted oncogene-addicted NSCLC (2024)
* ESMO rare neuroendocrine tumor (2024)
* ESMO Pan-Asian adapted biliary tract cancer (2024)
* ESMO Pan-Asian adapted gastric cancer (2024)
* ESMO insomnia (2023)
* EANO-ESMO leptomeningeal carcinomatosis (2023)
* ESMO anxiety and depression (2023)
* ESMO EoL (2023)
* ESMO-EURACAN salivary gland cancer (2022)
* EHNS-ESMO-ESTRO Pan-Asian adapted H&N cancer (2021)
* ESMO cancer cachexia (2021)
* ESMO dyspnea (2020)
* ESMO “orphan” symptoms (2020)
* AIOM early colon cancer (2020)
* AIOM metastatic colorectal cancer (2017)
Other
* Created HER2-low page and moved Destiny-Breast04 and NSABP B-47 to this page
* Created Pharmacy Editors section on the Editorial Board page and added details for the pharmacy editors
* Reorganized the HemOnc.org Glossary
* 500+ reciprocal effect sizes/hazard ratios added to control arms
* Historical ALK+ NSCLC page created; chemotherapy regimens moved to this page
* Created camizestrant and giredestrant pages
* Began to replace generic “superior/inferior” efficacy statements with time-based statements for survival endpoints (“longer/shorter”) and quantified statements for rate-based endpoints (“higher/lower”)
Selected links
# SC nivolumab: https://hemonc.org/wiki/Clear_cell_renal_cell_carcinoma#Nivolumab_and_hyaluronidase_monotherapy
# HER2-low page: https://hemonc.org/wiki/Breast_cancer,_HER2-low
==HemOnc.org Weekly Content Update (December 23-29, 2024)==
===New Regimens===
*ADT & Darolutamide for mHSPC
*Gefitinib monotherapy for refractory esophageal cancer (historical)
*CP & Cetuximab for first-line NSCLC (historical)
===New Studies===
*CALGB A071102 (negative RCT of TMZ + veliparib vs TMZ alone in adjuvant glioblastoma)
*NRG-GY005 (negative RCT of cediranib or cediranib/olaparib vs SOC in platinum-resistant ovarian cancer)
*ANITA (negative RCT of atezolizumab combined with platinum-based chemotherapy followed by maintenance niraparib in platinum-sensitive ovarian cancer)
*ARANOTE (positive phase 3 of darolutamide and ADT without chemotherapy in patients with mHSPC)
*M14TIL (positive phase 3 of TILs vs ipilimumab in second-line melanoma, published in 2022)
*Ferry et al. 2007 (phase 2 of gefitinib in esophageal cancer, basis of COG-esoph phase 3 RCT)
===New Study Updates===
*PRO analysis of CHART (prostate cancer)
*Efficacy update of CheckMate 274 (urothelial carcinoma)
*Update of C-144-01 (melanoma; published in 2022)
===Other===
*2024 ASCO Anal Cancer guideline
*Nivolumab and hyaluronidase (Opdivo Qvantig) page created
*Historical esophageal cancer page created
*Began adding reciprocal effect sizes/hazard ratios to control arms
===Selected links===
#ARANOTE
#ASCO Anal Cancer Guidelines
Category:General reference pages